Moreover, although programmed death ligand 1 (PD‐L1) expression and tumour mutational burden have been investigated as predictive markers, they have not exhibited significant predictive value, as both the high and low PD‐L1 expression groups experience similar benefits from checkpoint inhibitors. The gene discussed is CD274; the disease is neoplasm.